Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hematology

Navigating Complications: Inhibitors & Joint Health

At a Glance

The two main complications of hemophilia are inhibitors (when the immune system attacks factor treatments) and hemophilic arthropathy (joint damage from repeated bleeding). Strict adherence to your preventative prophylaxis schedule is the best way to prevent both of these complications.

While modern treatments are highly effective, hemophilia still presents two significant challenges: inhibitors and joint damage (arthropathy). Understanding these complications early allows you and your care team to take aggressive steps to protect your long-term health [1][2].

Inhibitors: An Immune System “Mistake”

An inhibitor is an antibody produced by the immune system that mistakenly views the infused clotting factor as a foreign “invader” and attacks it. This neutralizes the factor, making the treatment ineffective at stopping a bleed [3][4].

  • How do I know if I have one? The most common and critical warning sign of an inhibitor is that your usual factor treatment stops working, or it takes much longer to stop a routine bleed. If your standard dose no longer controls the bleeding, contact your HTC immediately for a simple blood test to check for inhibitors.
  • Who is at risk? Inhibitors are most common in people with severe Hemophilia A, affecting approximately 25–40% of patients. In Hemophilia B, they are much rarer, affecting about 1–5% [3][5].
  • When do they occur? They most often appear within the first 50 “exposure days” (days when factor is infused), particularly in the first 10 days [6][7].
  • How are they managed?
    • Bypassing Agents: Since the “normal” factor is being blocked, doctors use bypassing agents like recombinant Factor VIIa (rFVIIa) or activated prothrombin complex concentrates (aPCC). These “skip” the blocked part of the clotting cascade to help the blood clot [8][9].
      • CRITICAL SAFETY WARNING: If you are taking Emicizumab (Hemlibra), the concurrent use of aPCC carries a very high risk of severe complications, including Thrombotic Microangiopathy (TMA) and severe blood clots (thromboembolic events). Patients on Emicizumab must strictly avoid or severely limit aPCC use, guided only by their hematologist [10].
    • Immune Tolerance Induction (ITI): This is the gold-standard treatment to get rid of an inhibitor. It involves giving frequent, often daily, doses of factor over many months to “teach” the immune system to tolerate the protein [11][2]. ITI is successful in about 70% of cases [12].

Hemophilic Arthropathy: The Cost of Bleeding

Repeated bleeding into a joint is the leading cause of disability in hemophilia. This process is called hemophilic arthropathy [13][14].

  1. The Iron Problem: Blood contains iron. When blood enters a joint, the iron (hemosiderin) deposits into the joint lining and cartilage. This iron is toxic to the joint and causes a form of iron-induced cell death [15][16].
  2. Inflammation (Synovitis): The joint lining (synovium) becomes inflamed and swollen as it tries to clean up the blood. This inflamed lining becomes very fragile and full of new blood vessels, making it even more likely to bleed again—a “vicious cycle” [17][18].
  3. Cartilage Destruction: Over time, the chronic inflammation and iron deposits eat away at the smooth cartilage that cushions the joint, eventually leading to “bone-on-bone” arthritis, pain, and loss of motion [13][19].

Prevention is the Best Medicine

The single most important way to prevent both inhibitors and joint damage is strict adherence to your prophylaxis (preventative treatment) schedule. By keeping factor levels steady, you prevent the “breakthrough” bleeds that cause joint damage and reduce the need for high-dose rescue treatments that can sometimes trigger an immune response [20][1].

If a joint becomes a “target joint” (bleeding repeatedly in the same spot), your care team may recommend physical therapy, specialized imaging like ultrasound, or temporary adjustments to your factor dose to break the cycle of inflammation [21][22].

Common questions in this guide

How do I know if I have developed a hemophilia inhibitor?
The most common warning sign is that your usual factor treatment stops working or takes much longer to stop a routine bleed. If your standard dose no longer controls bleeding, contact your Hemophilia Treatment Center immediately for a simple blood test.
What is Immune Tolerance Induction (ITI) for hemophilia?
ITI is the gold-standard treatment to eliminate an inhibitor by teaching the immune system to tolerate the clotting factor. It involves giving frequent, often daily, doses of factor over many months and is successful in about 70% of cases.
Why does bleeding cause joint damage in hemophilia?
Blood contains iron, which is toxic to the joint lining and cartilage. Repeated bleeding causes chronic inflammation and deposits iron that eats away at the cartilage, eventually leading to arthritis, pain, and loss of joint motion.
What are bypassing agents and when are they used?
Bypassing agents are used when a patient develops an inhibitor that neutralizes their normal factor treatment. These medications help the blood clot by skipping over the blocked part of the clotting cascade.
How can I prevent hemophilic arthropathy (joint damage)?
The most effective way to prevent joint damage is strict adherence to your prophylaxis (preventative treatment) schedule. By keeping your factor levels steady, you prevent the breakthrough bleeds that trigger inflammation and long-term joint destruction.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my/my child's inhibitor level been measured recently, and what is the current titer in Bethesda Units (BU)?
  2. 2.Is Immune Tolerance Induction (ITI) an option for us, and what would the daily infusion schedule look like?
  3. 3.If an inhibitor is present, which bypassing agent (rFVIIa or aPCC) should we keep on hand for breakthrough bleeds, considering any other medications we are taking?
  4. 4.Are there signs of 'synovitis' or inflamed joint lining on an ultrasound, even if the joint doesn't look swollen?
  5. 5.How can we adjust our treatment plan to prevent long-term iron-related damage in the joints after a bleed?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.

    Abdelgawad HAH, Foster R, Otto M

    Blood reviews 2024; (64()):101164 doi:10.1016/j.blre.2023.101164.

    PMID: 38216442
  2. 2

    Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success.

    Elalfy M, Elghamry I, Hassab H, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2022; (28(1)):65-72 doi:10.1111/hae.14456.

    PMID: 34797008
  3. 3

    Molecular Mechanisms of Inhibitor Development in Hemophilia.

    Tieu P, Chan A, Matino D

    Mediterranean journal of hematology and infectious diseases 2020; (12(1)):e2020001 doi:10.4084/MJHID.2020.001.

    PMID: 31934311
  4. 4

    Missense and nonsense mutations and inhibitor development in patients with hemophilia A and B.

    Karimi F, Saki N, Khademi R, et al.

    Journal of thrombosis and thrombolysis 2026; (59(1)):210-219 doi:10.1007/s11239-025-03171-6.

    PMID: 40879869
  5. 5

    Frequency of T Regulatory Cells Subpopulations in Hemophilia A Patients with Inhibitors.

    Arreola-Díaz R, Hernández-Juárez J, Ricardo-Moreno T, et al.

    Hamostaseologie 2026; doi:10.1055/a-2698-0263.

    PMID: 41628641
  6. 6

    Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.

    Peyvandi F, Cannavò A, Garagiola I, et al.

    Journal of thrombosis and haemostasis : JTH 2018; (16(1)):39-43 doi:10.1111/jth.13888.

    PMID: 29080391
  7. 7

    Immunotolerance induction effectivity in hemophilia A children and neutralizing alloantibodies.

    Soto A V, Cortez S D, González S M

    Revista chilena de pediatria 2020; (91(2)):232-238 doi:10.32641/rchped.v91i2.1364.

    PMID: 32730542
  8. 8

    Therapeutic plasma exchange as part of multimodal treatment of acquired hemophilia in a patient with concurrent acute intracerebral bleed and pulmonary embolism.

    Wool GD, Chapel D, Treml A, Miller JL

    Transfusion 2017; (57(7)):1827-1832 doi:10.1111/trf.14132.

    PMID: 28436106
  9. 9

    Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile.

    Lillicrap D, Schiviz A, Apostol C, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2016; (22(2)):308-317 doi:10.1111/hae.12784.

    PMID: 26278557
  10. 10

    European principles of inhibitor management in patients with haemophilia: implications of new treatment options.

    Hermans C, Giangrande PLF, O'Mahony B, et al.

    Orphanet journal of rare diseases 2020; (15(1)):219 doi:10.1186/s13023-020-01511-8.

    PMID: 32831110
  11. 11

    Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.

    Carcao M, Shapiro A, Staber JM, et al.

    Haemophilia : the official journal of the World Federation of Hemophilia 2018; (24(2)):245-252 doi:10.1111/hae.13413.

    PMID: 29436077
  12. 12

    Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study.

    Antun A, Monahan PE, Manco-Johnson MJ, et al.

    Journal of thrombosis and haemostasis : JTH 2015; (13(11)):1980-8 doi:10.1111/jth.13143.

    PMID: 26382916
  13. 13

    The good, the bad and the ugly of pain in haemophilia: Recent evidence on the epidemiology, molecular mechanisms and knowledge gaps preventing optimal treatment.

    Benemei S, Mattia C, Di Minno MND

    Haemophilia : the official journal of the World Federation of Hemophilia 2024; (30(3)):589-597 doi:10.1111/hae.15002.

    PMID: 38545868
  14. 14

    The current role of orthoses in treating haemophilic arthropathy.

    De la Corte-Rodriguez H, Rodriguez-Merchan EC

    Haemophilia : the official journal of the World Federation of Hemophilia 2015; (21(6)):723-30 doi:10.1111/hae.12779.

    PMID: 26248876
  15. 15

    MR Imaging of Hemosiderin Deposition in the Ankle Joints of Patients with Haemophilia: The Contribution of a Multi-Echo Gradient-Echo Sequence-Correlation with Osteochondral Changes and the Number and Chronicity of Joint Bleeds.

    Papakonstantinou O, Karavasilis E, Martzoukos E, et al.

    Life (Basel, Switzerland) 2024; (14(9)) doi:10.3390/life14091112.

    PMID: 39337896
  16. 16

    Ferroptosis: a new target for iron overload-induced hemophilic arthropathy synovitis.

    Han Z, Zheng L, Luo D, et al.

    Annals of hematology 2023; (102(5)):1229-1237 doi:10.1007/s00277-023-05190-w.

    PMID: 36951967
  17. 17

    The role of orthopaedic surgery in haemophilia: current rationale, indications and results.

    Rodríguez-Merchán EC

    EFORT open reviews 2019; (4(5)):165-173 doi:10.1302/2058-5241.4.180090.

    PMID: 31191984
  18. 18

    Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice.

    Cooke EJ, Wyseure T, Zhou JY, et al.

    Journal of thrombosis and haemostasis : JTH 2019; (17(11)):1815-1826 doi:10.1111/jth.14567.

    PMID: 31301687
  19. 19

    Effect of Blood on Synovial Joint Tissues: Potential Role of Ferroptosis.

    Nicholson HJ, Sakhrani N, Rogot J, et al.

    Applied sciences (Basel, Switzerland) 2024; (14(14)) doi:10.3390/app14146292.

    PMID: 39619606
  20. 20

    From a bispecific monoclonal antibody to gene therapy: A new era in the treatment of hemophilia A.

    Mihaila RG

    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2023; (167(1)):1-8 doi:10.5507/bp.2022.046.

    PMID: 36413008
  21. 21

    Merging into the mainstream: the evolution of the role of point-of-care musculoskeletal ultrasound in hemophilia.

    Bakeer N, Shapiro AD

    F1000Research 2019; (8()) doi:10.12688/f1000research.16039.1.

    PMID: 31431824
  22. 22

    The hidden joint in children with haemophilia on prophylaxis.

    Daffunchio C, Galatro G, Faurlin V, et al.

    Thrombosis research 2023; (226()):86-92 doi:10.1016/j.thromres.2023.04.012.

    PMID: 37130495

This page provides educational information about hemophilia complications such as inhibitors and joint damage. Always consult your hematologist or Hemophilia Treatment Center before adjusting treatments or if you suspect an inhibitor.

Get notified when new evidence is published on Hemophilia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.